FlexDex Revenue and Competitors
Estimated Revenue & Valuation
- FlexDex's estimated annual revenue is currently $3.4M per year.
- FlexDex's estimated revenue per employee is $112,000
Employee Data
- FlexDex has 30 Employees.
- FlexDex grew their employee count by 20% last year.
FlexDex's People
Name | Title | Email/Phone |
---|
FlexDex Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $56.4M | 322 | 7% | N/A | N/A |
#2 | $3.6M | 32 | 28% | N/A | N/A |
#3 | $1080M | 65 | 18% | $700M | N/A |
#4 | $5.4M | 48 | 4% | N/A | N/A |
#5 | $133.4M | 0 | N/A | $1.4M | N/A |
#6 | $1.2M | 14 | N/A | N/A | N/A |
#7 | $3.4M | 30 | 20% | N/A | N/A |
#8 | $2.5M | 25 | 4% | N/A | N/A |
#9 | $6.6M | 54 | -29% | $31.5M | N/A |
#10 | $1.5M | 18 | 0% | N/A | N/A |
What Is FlexDex?
We believe that every surgical instrument should function like a surgeon's hand and effortlessly transform instinct into action. To improve patient care everywhere, cost and complexity must be avoided. Our deliberate focus on efficient and elegant design extends intuitive control to basic mechanical instruments. Developed at the University of Michigan Precision Systems Design Lab (http://psdl.engin.umich.edu), the patented Virtual Centerâ„¢ of FlexDex is a simple mechanical design based on novel parallel-kinematics. Our low cost scalable technology that will greatly enhance the capabilities surgical instruments and endoscopes globally. **If you would like to file a complaint regarding FlexDex products, please contact the FlexDex Quality Department at feedback@flexdex.com, or +001 (810) 775-3353.
keywords:N/AN/A
Total Funding
30
Number of Employees
$3.4M
Revenue (est)
20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.8M | 30 | 7% | N/A |
#2 | $5.5M | 31 | 0% | N/A |
#3 | $3.7M | 31 | -14% | N/A |
#4 | $6.7M | 31 | -9% | N/A |
#5 | $6.2M | 31 | 3% | N/A |